• Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2020 year
    20 day
    Asahi Kasei and Winhealth Pharma Group reach strategic cooperation on Naftopidil®

    (October 12th, 2020, Hangzhou) Asahi Kasei Pharmaceutical Co., Ltd. (hereinafter referred to as 'Asahi Kasei') and Hongkong Winhealth Pharma Group Co., Ltd. (hereinafter referred to as 'Winhealth Pharma Group') held an online signing ceremony in Tokyo (Japan) and Hangzhou, announcing the strategic cooperation between the two parties: Asahi Kasei, as the license holder and manufacturer of its important product Naftopidil® (whose generic name is Naftopidil Tablets), granted the commercialization right of Naftopidil® in Mainland China to Winhealth Pharma Group from August 10, 2020.

     Asahi Kasei and Winhealth Pharma Group reach strategic cooperation on Naftopidil®

    Group photo of online signing ceremony between between two parties (October 12th, 2020, Hangzhou) 

    As a special α1- receptor blocker for the treatment of dysuria caused by benign prostatic hyperplasia, Naftopidil® has been sold in Japan since February 1999. On May 20, 2020, Asahi Kasei obtained the marketing approval for the original drug product in China.

    According to the data of the National Bureau of Statistics of China, there were 253.88 million people aged 60 and above in 2019, accounting for 18.1% of the total population in Mainland China at the end of the year, including 176.03 million people aged 65 and above, accounting for 12.6% of the total population in Mainland China at the end of the year. [1] With the aging of China's population, there are more and more patients with dysuria due to benign prostatic hyperplasia. From the perspective of improving patients' QOL (quality of life), it becomes increasingly important to treat dysuria.

    Mr. Aoki Hiroshi, President of Asahi Kasei Pharmaceutical Co., Ltd., said, 'With its mission of 'saving patients' lives, improving patients' quality of life and providing the most suitable services and solutions to medical workers', Asahi Kasei has actively launched drugs that meet clinical needs in markets outside Japan such as China and the United States, and has made due contributions to the healthy development of the world. In 2018, we signed an entrustment agreement Winhealth Pharma Group related to the Eril® business, and established a close cooperative relationship with it. We are very happy that both sides cooperated again in August this year. We have learned that with the aging of China's population in recent years, the number of patients with dysuria caused by prostatic hyperplasia is increasing in China, and the importance of treatment is also increasing. We firmly believe that Naftopidil can provide a new choice for the treatment of patients with dysuria in China, and thus improve the quality of life of such patients. '

    Mr. Wang Wei, founder, board chairman and CEO of Hongkong Winhealth Pharma Group Co., Ltd, pointed out, 'We are very happy to have cooperated with Asahi Kasei again. Since its establishment 14 years ago, Winhealth Pharma Group has taken the mission of 'providing patients with timely and effective clinical treatment'. With the support from both the Mature Drug Division (EPD) and Innovative Medical Instrument Division (ITD), it aims to continuously introduce global excellent drugs to the domestic market to meet more unmet needs of patients. Specifically, urology and male and female health are one of our important fields. Therefore, after Naftopidil was recently launched, we started to introduce this variety. The introduction of Naftopidil will further enrich and strengthen our product portfolio in the field of urology. With the joint efforts of both parties, we look forward to deepening cooperation, working hand in hand to plough into the health cause, and providing dysuria patients with practical and effective help and solutions.'

    About Winhealth Pharma Group

    Hongkong Winhealth Pharma Group Co., Ltd. is an innovative pharmaceutical company established in Hong Kong and targeting Mainland China. Being dedicated to introducing and commercializing patents to meet the huge medical demands in the Greater China market, it is divided into two sections: Mature Drug Division (EPD) and Innovative Drug Division (ITD) centering on rare diseases. Specifically, the Mature Drug Division (EPD) covers respiratory diseases and anti-infection, cardiovascular diseases, digestive and hepatic diseases, skin and medical cosmetology, urinary system diseases and other fields. By offering integrated services of local R&D, registration and commercialization to internationally renowned pharmaceutical companies, Winhealth Pharma Group has become one of the well-known CDCO (Contract Development and Commercialization Organization) groups in China, and its customers include many Top 500 multinational pharmaceutical companies in the world. Headquartered in Chinese Hong Kong, the Company has operation centers and offices in Hangzhou, Shanghai, Beijing, Guangzhou, Hainan, Tokyo and Munich. Please visit for more information.

    About Asahi Kasei

    Established in 1922, Asahi Kasei Co., Ltd. is headquartered in Tokyo, Japan, and is a large comprehensive chemical company in Japan. Being active in the fields of petrochemical industry, plastics, building materials, housing, fiber and textiles, medicine, medical treatment, etc., it is committed to making contributions to the 'life' and 'living' of people around the world.

    Its pharmaceutical business covers drugs and diagnostic reagents. In the field of medical drugs, with orthopedics as the core, it has constantly launched many new drugs in urology, central nervous system, immunity, blood and circulatory organs, etc. Meanwhile, as an outstanding R&D pharmaceutical enterprise, it is dedicated to developing new drugs for general purposes in the world.

    Visit for more information.


    []The data comes from the 'Statistical Communique on the National Economic and Social Development in 2019 of the People's Republic of China' (February 28, 2020) of the National Bureau of Statistics of China, and does not include the number of people in Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan Province and overseas Chinese.


    Forward-looking statements 

    This announcement contains forward-looking statements, which reflect the current beliefs and expectations of the management of Hongkong Winhealth Pharma Group Co., Ltd. These statements are based on the expectation and assumption of available information at present. Due to some known and unknown risks and uncertainties, the actual results may be significantly different from the statements. The risks and uncertainties include domestic and international macroeconomic conditions, such as overall market conditions and changes in interest rates and currency exchange rates. Forward-looking statements related to products are particularly applicable to such risks and uncertainties. The product risks and uncertainties include but are not limited to the completion and termination of clinical trials, obtaining the approval from the regulatory authorities, declarations and concerns about product safety and effectiveness, technical progress, adverse results of important lawsuits, medical reform and changes of laws and regulations at home and abroad. In addition, the manufacturing and marketing risks of existing products include but are not limited to: production capacity failing to meet the demand, the accessibility of raw materials, the entry of competitive products into the market, and force majeure. We have no intention or obligation to update or change any forward-looking statements whether due to new information, future events or other circumstances.


    For media enquiries, please contact:

    Hongkong Winhealth Pharma Group Co., Ltd

    Enterprise Publicity Department

    Wu Yuancheng

    Telephone: +86 157 0008 3612


    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.